Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Effectiveness of mobile-based monitoring system (ONKOSIS) in the management of chemotherapy-related symptoms: a randomized controlled trial.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05946070 (Effectiveness of Mobile Based Monitoring System in the Management of Chemotherapy-Related Symptoms), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effectiveness of Mobile Based Monitoring System in the Management of Chemotherapy-Related Symptoms
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeThis study was conducted to evaluate the impact of the ONKOSIS mobile application, developed within the scope of the study, on the management of chemotherapy-related symptoms and quality of life.
methodsThis randomized controlled, single-blind experimental design study was carried out with the participation of 199 patients at the Kocaeli University Semahat Aracı Oncology and Palliative Care Center, Outpatient Chemotherapy Unit. In the study, which used simple randomization, the intervention group consisted of 98 patients and the control group consisted of 101 patients. During chemotherapy treatment, in addition to standard care for symptom management, the intervention group used the ONKOSIS mobile application, while the control group used a demo mobile application. The study data were obtained through the Diagnostic Form, Nightingale Symptom Assessment Scale, Coping with Chemotherapy Symptoms Form, and patient satisfaction survey. The follow-up frequency was planned according to the type of treatment protocol applied to the patients. Patients who received four cycles of treatment were followed up after the 2nd, 3rd, and 4th cycles, while patients who received six cycles of treatment were followed up after the 2nd, 4th, and 6th cycles.
resultsThe study group had a mean age of 47.18 ± 13.83; 74.4% were female. Treatment cycles of 2, 3, or 4 weeks were provided for 26.6% of patients receiving treatment for gastrointestinal cancer, 21.6% for breast cancer, and 17.1% for lung cancer. Sociodemographic and clinical characteristics were similar between groups. Although the intervention group exhibited greater initial symptom burden (higher N-SAS scores at T1/T2), their symptom trajectory improved significantly over time compared to the control group, supporting the role of mHealth in enhancing outcomes. The use of ONKOSIS improved quality of life and patient satisfaction but did not reduce unscheduled healthcare visits.
conclusionThe ONKOSIS mobile application was found to be an effective tool in supporting symptom management and improving the quality of life for cancer patients during the treatment process. It was determined that the widespread adoption of the mobile application in cancer care could contribute to improving patient outcomes and enhancing care quality.
trial registrationClinicalTrials.gov ID: NCT05946070. Registered on June 22, 2023.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.